EPGL Company info 08/22/2014 11:21:26 $EPGL
Nice..
What was the name?
Welcome to the land of longs
EPGL Stock Message Board http://investorshangout.com/EP-Global-Communi...PGL-87206/
4.5B (Hayes and PWC) vs .5B (float)
I would be up for share reduction as long as the MAJOR portion is by the big boys if not all.
The float is 10% of total shares.
Just my opinion..
MPDD DEVICE ESTIMATED $4.5 BILLION DOLLARS ANNUALLY REVENUE
EPGL Medical Sciences, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body. The combined national and international market for the MPDD device is estimated at $4.5 billion dollars annually in device sales and recurrent education and training revenues.
I owned a stock hat did a share reduction with the stock owned by mgt and did not touch retail holders. Was a win win for mgt and investors.
July 8th Email response about Uplisting and SEC Fillings.
My EMAIL
Badali Wala <badaliwala@gmail.com>
Jul 8
to investors
Hello
Mr. Brady Peterson
I am EPGL shareholder. EPGL is going to uplist on higher exchange.
I believe EPGL is only need .10 for QX US but I strongly believe EPGL also have everything to go QX US Premium with 1.00 PPS.
Please let me know EPGL is going to uplisitn QX US or QX US PREMIUM.
thanks
Badali
EPGL Response
Investors EPGLMed.com
Jul 9
to me
Hi Badali,
Our team is looking at all options. We can tell you that QX, QX Premium and NASDAQ would be the considered tiers as you are aware. NASDAQ would be more likely for EPGL at that level than QX Premium, but all options are on table.
We will keep shareholders posted. SEC filings will be first thing to watch for.
Best,
EPGL IR Team
I'm in finally. Almost pulled the trigger at .04. Oh well. Better late than never
#4 most read, wow, #2 in sight. How many are ready to push the buy button?
EPGL
SEC Approves Alternative NASDAQ Listing Requirements
Posted on May 14, 2012 by RedChip Blogger
A recent change in the listing requirements for the NASDAQ Capital Market gives more small-cap companies the opportunity to uplist to the senior exchange.
On April 18, the Securities and Exchange Commission approved an alternative to the $4 initial listing bid price requirement for the NasdaqCM. The rule change is meant to level the playing field between the NASDAQ Stock Market and its main competitor, the NYSE Amex. Prior to the rule change, the NYSE Amex required companies to have a minimum stock price of $2 to $3, while the NasdaqCM required a price of $4. As a result, numerous small-cap stocks trading between $2 and $4 were shut out of the NasdaqCM. According to the NASDAQ Stock Market’s proposal, filed in January, “A number of companies have indicated a preference to initially list on the Capital Market instead of NYSE Amex and have expressed frustration at their inability to do so without reverse splitting their stock.”
Under the new NasdaqCM requirements, a stock can qualify for listing if it closes at $3 or above for at least five consecutive business days prior to approval. The five-day requirement is in place to reduce the risk of price manipulation aimed at allowing a security to qualify for listing. In addition to the $3 share price requirement, the company must meet the following requirements:
Stockholders’ equity of at least $5 million
Market value of publicly held shares of at least $15 million
Two years of operating history
Or:
Net income from continuing operations of $750,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years
Stockholders’ equity of at least $4 million
Market value of publicly held shares of at least $5 million.
Securities with a $2 minimum closing price for five consecutive business days prior to the approval can also qualify for listing on the NasdaqCM if they meet the Market Value of Listed Securities Standard, which requires a market value of listed securities of at least $50 million, stockholders’ equity of at least $4 million, and a market value of publicly held shares of at least $15 million
In addition, companies must demonstrate that they have more than $2 million in net tangible assets if they have been in continuous operation for at least three years, or more than $5 million if they’ve been in continuous operation for less than three years. A company must also have average revenue of at least $6 million for the past three years. All other requirements for listing on the Capital Market are the same or higher than those of the NYSE Amex. A copy of the NASDAQ Stock Market’s original proposal is available on the SEC website.
With the new requirements, the NASDAQ Stock Market becomes more competitive with the NYSE Amex, and emerging growth companies now have another avenue to benefit from the increased exposure, liquidity, and access to capital that comes with uplisting to a senior exchange. As would be expected, two companies that RedChip helped uplist, L & L Energy (NASDAQ: LLEN) and Longwei Petroleum (NYSE Amex: LPH), both saw substantial valuation gains after moving to senior exchanges. Other RedChip clients that could qualify for uplisting over the next 6 to 12 months include ChromaDex Corp. (OTC BB: CDXC), a natural products company and producer of the dietary supplement BluScience; First Surgical Partners Inc. (OTC BB: FSPI), a dividend-paying operator of ambulatory surgical centers; and Cross Border Resources, Inc. (OTC QX: XBOR), an oil and gas company operating in the Permian Basin. If you are an executive or board member of an over-the-counter company and would like to learn how RedChip can help your company, contact us today.
http://www.redchip.com/blog/index.php/uncateg...dm5o6XZRzs
weet about IP
EPGL Med ?@EPGLMed 8 May
a technological company can own. EPGL shareholders can submit any questions they may have to Brady Peterson at investors@epglmed.com
Expand
EPGL Med ?@EPGLMed 8 May
and of course, no sales. IP comes first, then everything follows after that. Intellectual properties are the most valuable assets...
Expand
EPGL Med ?@EPGLMed 8 May
extremely important asset to technological and medical device companies. Without IP, there are no devices and no FDA clearances...
Expand
EPGL Med ?@EPGLMed 8 May
In addition to Topspin, EPGL owns Intellectual Property in several new devices under development. Intellectual Property or IP is an...
Expand
EPGL Med ?@EPGLMed 8 May
Today, EPGL filed another patent for the Topspin technology. The Topspin technology is the single most valuable IP EPGL owns presently.
Rather than a RS, I'd like to see a 3rd party buyout AJW's shares and then retire some of them along with some of Mr. Hayes' shares.
Based on managements repeated pubic statements I think another reverse split can be eliminated from conversation at this point. Longs voted in favor of it once knowing it would help to get us in the right direction. I for one would never vote in favor of another. Further, share retirement would be a much better way to accomplish the same thing. Mr. Hayes has not eliminated that as a future possibility. Given the tech EPGL has I think the necessary pps for up listing will happen organically just based on licensing revenue through partnership deals alone. Even with the large AS structure since the float is what retail investors can actually buy into and that is Very limited.
EPGL Med ?@EPGLMed 12h
to latest OTC Annual Report Regarding Current Share Structure or Email Brady Peterson @ Investors@epglmed.com with Any Questions...
Expand
EPGL Med ?@EPGLMed 12h
EPGL Shareholder Alert: In Response to Some Email Questions; EPGL Share Structure and Float Remains Unchanged. Shareholders Should refer..
https://twitter.com/EPGLMed
Mr Hayes sounded pretty darn confident and convincing that they will not do this again. He obviously has VERY high expectations for this company as we all should. If what they have been developing turns into fruition and they are the leader of this new wave of biomems tech, then an RS is nowhere in the cards.
No R/S here. Only buy back share will happen.
In accordance with the 2012 restructuring Agreement EPGL has acquired the option and right of first refusal to all AJW / Pricewaterhouse Cooper controled holding. This includes up to 2.25 billion restricted common shares.
The preceding information is provided as supplemental to the Annual report dated December 31, 2012
https://www.otciq.com/otciq/ajax/showFinancia...f?id=98547
Let s not forget that the pps alone doesn't really matter. It matters only as a threshold for some exchanges such as the nasdaq. For market cap we must also take into account the sheer number of shares.
With current share structure, epgl should be worth 20 billion $ to be on the nasdaq.
Is it possible ? Well, the float is very tight, that helps... and if epgl tech does become a standard in the wearable devices market, this is achievable even before actual revenue "justifies" it. It happens a lot in the high tech field.
But a change in the share structure could help as well and make 4$ a share more easily reachable. The best solution for us would be share buyback and retirement but a rs could do the trick at some point. And if it can help increasing the market cap, as there are more investors in the nasdaq, I think it should be consider as a possibility.
True. Though I would not really mind a rs in the future if the goal is to reach the required threshold for nasdaq. As long as it is not coming with dilution (so the a/s and o/s have to be reduced too) it would be acceptable.
I think that in the long run the company could potentially reach nasdaq without it but if management thinks it is a good way to unlock value, I believe it would be fair to consider it. I mean that kind of rs would not be the usual dumping move performed in the usual pinkies
Which one was it that is now 157?
I know another one... I still own, pcy$
Nice..
What was the name?
Welcome to the land of longs
EPGL Stock Message Board http://investorshangout.com/EP-Global-Communi...PGL-87206/
4.5B (Hayes and PWC) vs .5B (float)
I would be up for share reduction as long as the MAJOR portion is by the big boys if not all.
The float is 10% of total shares.
Just my opinion..
MPDD DEVICE ESTIMATED $4.5 BILLION DOLLARS ANNUALLY REVENUE
EPGL Medical Sciences, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body. The combined national and international market for the MPDD device is estimated at $4.5 billion dollars annually in device sales and recurrent education and training revenues.
I owned a stock hat did a share reduction with the stock owned by mgt and did not touch retail holders. Was a win win for mgt and investors.
July 8th Email response about Uplisting and SEC Fillings.
My EMAIL
Badali Wala <badaliwala@gmail.com>
Jul 8
to investors
Hello
Mr. Brady Peterson
I am EPGL shareholder. EPGL is going to uplist on higher exchange.
I believe EPGL is only need .10 for QX US but I strongly believe EPGL also have everything to go QX US Premium with 1.00 PPS.
Please let me know EPGL is going to uplisitn QX US or QX US PREMIUM.
thanks
Badali
EPGL Response
Investors EPGLMed.com
Jul 9
to me
Hi Badali,
Our team is looking at all options. We can tell you that QX, QX Premium and NASDAQ would be the considered tiers as you are aware. NASDAQ would be more likely for EPGL at that level than QX Premium, but all options are on table.
We will keep shareholders posted. SEC filings will be first thing to watch for.
Best,
EPGL IR Team
I'm in finally. Almost pulled the trigger at .04. Oh well. Better late than never
#4 most read, wow, #2 in sight. How many are ready to push the buy button?
EPGL
SEC Approves Alternative NASDAQ Listing Requirements
Posted on May 14, 2012 by RedChip Blogger
A recent change in the listing requirements for the NASDAQ Capital Market gives more small-cap companies the opportunity to uplist to the senior exchange.
On April 18, the Securities and Exchange Commission approved an alternative to the $4 initial listing bid price requirement for the NasdaqCM. The rule change is meant to level the playing field between the NASDAQ Stock Market and its main competitor, the NYSE Amex. Prior to the rule change, the NYSE Amex required companies to have a minimum stock price of $2 to $3, while the NasdaqCM required a price of $4. As a result, numerous small-cap stocks trading between $2 and $4 were shut out of the NasdaqCM. According to the NASDAQ Stock Market’s proposal, filed in January, “A number of companies have indicated a preference to initially list on the Capital Market instead of NYSE Amex and have expressed frustration at their inability to do so without reverse splitting their stock.”
Under the new NasdaqCM requirements, a stock can qualify for listing if it closes at $3 or above for at least five consecutive business days prior to approval. The five-day requirement is in place to reduce the risk of price manipulation aimed at allowing a security to qualify for listing. In addition to the $3 share price requirement, the company must meet the following requirements:
Stockholders’ equity of at least $5 million
Market value of publicly held shares of at least $15 million
Two years of operating history
Or:
Net income from continuing operations of $750,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years
Stockholders’ equity of at least $4 million
Market value of publicly held shares of at least $5 million.
Securities with a $2 minimum closing price for five consecutive business days prior to the approval can also qualify for listing on the NasdaqCM if they meet the Market Value of Listed Securities Standard, which requires a market value of listed securities of at least $50 million, stockholders’ equity of at least $4 million, and a market value of publicly held shares of at least $15 million
In addition, companies must demonstrate that they have more than $2 million in net tangible assets if they have been in continuous operation for at least three years, or more than $5 million if they’ve been in continuous operation for less than three years. A company must also have average revenue of at least $6 million for the past three years. All other requirements for listing on the Capital Market are the same or higher than those of the NYSE Amex. A copy of the NASDAQ Stock Market’s original proposal is available on the SEC website.
With the new requirements, the NASDAQ Stock Market becomes more competitive with the NYSE Amex, and emerging growth companies now have another avenue to benefit from the increased exposure, liquidity, and access to capital that comes with uplisting to a senior exchange. As would be expected, two companies that RedChip helped uplist, L & L Energy (NASDAQ: LLEN) and Longwei Petroleum (NYSE Amex: LPH), both saw substantial valuation gains after moving to senior exchanges. Other RedChip clients that could qualify for uplisting over the next 6 to 12 months include ChromaDex Corp. (OTC BB: CDXC), a natural products company and producer of the dietary supplement BluScience; First Surgical Partners Inc. (OTC BB: FSPI), a dividend-paying operator of ambulatory surgical centers; and Cross Border Resources, Inc. (OTC QX: XBOR), an oil and gas company operating in the Permian Basin. If you are an executive or board member of an over-the-counter company and would like to learn how RedChip can help your company, contact us today.
http://www.redchip.com/blog/index.php/uncateg...dm5o6XZRzs
weet about IP
EPGL Med ?@EPGLMed 8 May
a technological company can own. EPGL shareholders can submit any questions they may have to Brady Peterson at investors@epglmed.com
Expand
EPGL Med ?@EPGLMed 8 May
and of course, no sales. IP comes first, then everything follows after that. Intellectual properties are the most valuable assets...
Expand
EPGL Med ?@EPGLMed 8 May
extremely important asset to technological and medical device companies. Without IP, there are no devices and no FDA clearances...
Expand
EPGL Med ?@EPGLMed 8 May
In addition to Topspin, EPGL owns Intellectual Property in several new devices under development. Intellectual Property or IP is an...
Expand
EPGL Med ?@EPGLMed 8 May
Today, EPGL filed another patent for the Topspin technology. The Topspin technology is the single most valuable IP EPGL owns presently.
Rather than a RS, I'd like to see a 3rd party buyout AJW's shares and then retire some of them along with some of Mr. Hayes' shares.
Based on managements repeated pubic statements I think another reverse split can be eliminated from conversation at this point. Longs voted in favor of it once knowing it would help to get us in the right direction. I for one would never vote in favor of another. Further, share retirement would be a much better way to accomplish the same thing. Mr. Hayes has not eliminated that as a future possibility. Given the tech EPGL has I think the necessary pps for up listing will happen organically just based on licensing revenue through partnership deals alone. Even with the large AS structure since the float is what retail investors can actually buy into and that is Very limited.
EPGL Med ?@EPGLMed 12h
to latest OTC Annual Report Regarding Current Share Structure or Email Brady Peterson @ Investors@epglmed.com with Any Questions...
Expand
EPGL Med ?@EPGLMed 12h
EPGL Shareholder Alert: In Response to Some Email Questions; EPGL Share Structure and Float Remains Unchanged. Shareholders Should refer..
https://twitter.com/EPGLMed
Mr Hayes sounded pretty darn confident and convincing that they will not do this again. He obviously has VERY high expectations for this company as we all should. If what they have been developing turns into fruition and they are the leader of this new wave of biomems tech, then an RS is nowhere in the cards.
No R/S here. Only buy back share will happen.
In accordance with the 2012 restructuring Agreement EPGL has acquired the option and right of first refusal to all AJW / Pricewaterhouse Cooper controled holding. This includes up to 2.25 billion restricted common shares.
The preceding information is provided as supplemental to the Annual report dated December 31, 2012
https://www.otciq.com/otciq/ajax/showFinancia...f?id=98547
Let s not forget that the pps alone doesn't really matter. It matters only as a threshold for some exchanges such as the nasdaq. For market cap we must also take into account the sheer number of shares.
With current share structure, epgl should be worth 20 billion $ to be on the nasdaq.
Is it possible ? Well, the float is very tight, that helps... and if epgl tech does become a standard in the wearable devices market, this is achievable even before actual revenue "justifies" it. It happens a lot in the high tech field.
But a change in the share structure could help as well and make 4$ a share more easily reachable. The best solution for us would be share buyback and retirement but a rs could do the trick at some point. And if it can help increasing the market cap, as there are more investors in the nasdaq, I think it should be consider as a possibility.
True. Though I would not really mind a rs in the future if the goal is to reach the required threshold for nasdaq. As long as it is not coming with dilution (so the a/s and o/s have to be reduced too) it would be acceptable.
I think that in the long run the company could potentially reach nasdaq without it but if management thinks it is a good way to unlock value, I believe it would be fair to consider it. I mean that kind of rs would not be the usual dumping move performed in the usual pinkies
Which one was it that is now 157?
I know another one... I still own, pcy$
